Thomas S. Griffith

Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness.

Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.

TRAIL: a mechanism of tumor surveillance in an immune privileged site.

Cell death and immune privilege.

Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand.

Apoptosis, tolerance, and regulatory T cells--old wine, new wineskins.

The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.

Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation.

Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element.

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation.

Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells.

Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets.

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.

Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.

Neisseria gonorrhoeae delays the onset of apoptosis in polymorphonuclear leukocytes.

TRAIL deficiency delays, but does not prevent, erosion in the quality of "helpless" memory CD8 T cells.

Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.

A vision of cell death: Fas ligand and immune privilege 10 years later.

Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.

Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils.

Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.

The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.

Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL.

TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.

Predicting bacillus Calmette-Guerin immunotherapy effectiveness.

Cytomegalovirus and the role of interferon in the expression of tumor necrosis factor-related apoptosis-inducing ligand in the placenta.

TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules.

Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.

Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes.

Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.

High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.

Role of neutrophils in BCG immunotherapy for bladder cancer.

Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells.

CD8 T cells utilize TRAIL to control influenza virus infection.

High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.

The use of immunofluorescence in microdissection testicular sperm extraction.

TRAIL gene therapy: from preclinical development to clinical application.

Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats.

[Not Available].

Induction of tumor cell apoptosis by TRAIL gene therapy.

Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats.

In vivo fluorescence imaging is well-suited for the monitoring of adenovirus directed transgene expression in living organisms.

TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Activation-induced CD154 expression abrogates tolerance induced by apoptotic cells.

TRAIL-deficient mice exhibit delayed regression of retinal neovascularization.

The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism.

Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.

Micro-recanalization in a biodegradable graft for reconstruction of the vas deferens is enhanced by sildenafil citrate.

Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.

TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion.

NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.

Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Tracing of islet graft survival by way of in vivo fluorescence imaging.

Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent.

Description of a novel murine model for ileocystoplasty and early histologic changes.

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer.

The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL.

The plasticity of regulatory T cell function.

Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells.

Effect of Combined Locally Delivered Growth Factors and Systemic Sildenafil Citrate on Microrecanalization in Biodegradable Conduit for Vas Deferens Reconstruction.

Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.

Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth.

Therapeutic potential of VIP vs PACAP in diabetes.

Insulin gene therapy from design to beta cell generation.

TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.

Activation of systemic antitumor immunity via TRAIL-induced apoptosis.

Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection.

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.

T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Clinical utility of insulin and insulin analogs.

Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer.

Intravascular staining for discrimination of vascular and tissue leukocytes.

Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.

Polymicrobial sepsis alters antigen-dependent and -independent memory CD8 T cell functions.

GLP-1-mediated gene therapy approaches for diabetes treatment.

Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.

Minimal changes in the systemic immune response after nephrectomy of localized renal masses.

Impact of sepsis on CD4 T cell immunity.

CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.

Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function.

Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge.

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion.

Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis.

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.

Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity.

Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease.

Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo.

Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice.